DOI: 10.12890/2024_004876

Coexistence of HHV-8-associated plasmacytic multicentric Castleman disease, Kaposi’s sarcoma, and multiple myeloma in a HIV-negative patient

Authors

  • Rashad Ismayilov Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey
  • Olgu Erkin Cinar Department of Hematology, Hacettepe University Faculty of Medicine, Ankara, Turkey 0000-0003-1226-5797
  • Murat Ozdede Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey 0000-0002-6981-1210
  • Ece Ozogul Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey 0000-0002-8905-0199
  • Umit Yavuz Malkan Department of Hematology, Hacettepe University Faculty of Medicine, Ankara, Turkey 0000-0001-5444-4895
  • Aysegul Uner Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey 0000-0002-2522-1606
  • Ibrahim Halil Gullu Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey 0000-0002-6000-6311

ismayilov_r@hotmail.com

Keywords

Castleman disease, Kaposi’s sarcoma, multiple myeloma, HIV, HHV-8

Abstract

Background: Multicentric Castleman disease (MCD) is a rare, aggressive lymphoproliferative disorder. Human herpesvirus-8 (HHV-8) has an important role in the pathogenesis of the disease and its association with Kaposi’s sarcoma has been reported, especially in people living with human immunodeficiency virus (HIV). In this report, we present the case of HHV-8 positive MCD accompanied by Kaposi’s sarcoma and multiple myeloma in an HIV-negative patient.
Case Report: A 78-year-old man with Kaposi’s sarcoma presented with B symptoms, pancytopenia, lymphadenopathy, and splenomegaly. The bone marrow biopsy demonstrated 70% lambda-restricted monotypic plasma cell infiltration consistent with plasma dyscrasia. Also, the patient was diagnosed with HHV-8 positive MCD as a result of inguinal lymph node excisional biopsy. Treatment was initiated including ganciclovir and methylprednisolone and followed by rituximab. The patient passed away at the 24th hour of rituximab infusion due to shock.
Conclusions: MCD and associated malignancies are difficult to treat and have a poor prognosis. More studies and data are needed to manage these patients.

View the entire article

Downloads

References

  1. Ortega L, Cooper CJ, Otoukesh S, Mojtahedzadeh M, Didia CS, Torabi A, et al. Multicentric castleman’s disease and kaposi’s sarcoma in a HIV-positive patient on highly active antiretroviral therapy. Rare Tumors 2014;6:98–100.
  2. Carbone A, Borok M, Damania B, Gloghini A, Polizzotto MN, Jayanthan RK, et al. Castleman disease. Nat Rev Dis Prim Springer US 2021;7:84.
  3. Barbarov I, Koren-Michowitz M, Schiby G, Portnoy O, Livingstone D, Segal G. Fulminant HHV-8 associated Castleman’s disease in a non-HIV, Kaposi sarcoma patient with borderline hemophagocytic syndrome. Isr Med Assoc J 2015;17:253–255.
  4. Cervera Grau JM, Esquerdo GG, Ferrándiz CL, Garcia HB, Castellano MD, Moreno PF. Complete remission in a pancytopenic HIV negative, HHV-8 positive patient with multicentric Castleman’s disease induced with anti-CD20. Clin Transl Oncol 2006;8:540–541.
  5. Murphy C, Hawkes E, Chionh F, Chong G. Durable remission of both multicentric Castleman’s disease and Kaposi’s sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patient. J Clin Pharm Ther 2017;42:111–114.
  6. Hwang JP, Kim J, Park JM. Human immunodeficiency virus-negative multicentric castleman’s disease coexistent with kaposi’s sarcoma on18F-FDG PET/CT: A case report. Mol Clin Oncol 2019;10:318–320.
  7. Plachouri KM, Oikonomou C, Sarantopoulos A, Koumoundourou D, Georgiou S, Spiliopoulos T. Successful treatment and durable remission of human herpesvirus-8-induced Kaposi sarcoma and multicentric Castleman’s disease under valganciclovir in an HIV-negative patient. Dermatol Ther 2020;33:7–8.
  8. Gunduz E, Ozdemir N, Bakanay SM, Karakus S. A Rare Lymphoproliferative Disease: Castleman Disease. Turkish J Hematol 2021;38:314–320.
  9. Casper C, Teltsch DY, Robinson D, Desrosiers MP, Rotella P, Dispenzieri A, et al. Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease. Br J Haematol 2015;168:82–93.
  10. Sadeghian MH, Katebi M, Ayatollahi H, Keramati MR. Immunohistochemical study association between human herpesvirus 8 and multiple myeloma. Int J Hematol 2008;88:283–286.
  11. Ismail SI, Mahmoud IS, Salman MAL, Sughayer MA, Mahafzah AM. Frequent detection of Human Herpes Virus-8 in bone marrow of Jordanian patients of multiple myeloma. Cancer Epidemiol 2011;35:471–474.
  12. Kahouli S, Zahid H, Benkirane M, Messaoudi N. Association between Kaposi´s sarcoma and multiple myeloma: is it caused by HHV-8? PanAfrican Med J 2020;36:1–5.
  13. Lomas OC, Streetly M, Pratt G, Cavet J, Royston D, Schey S, et al. The management of Castleman disease. Br J Haematol 2021;195:328–337.
  14. Kulkarni HS. Rituximab and Cytokine Release Syndrome. Case Rep Oncol 2012;5:134-141.
  15. Patel AS, Geller RL, Goswami ND. Plasma Cell Variant Multicentric Castleman Disease and Kaposi’s Sarcoma in a Treatment-Naive HIV-Infected Patient. AIDS Res Hum Retroviruses 2018;34:127–128.
  16. Yang D, Zhou X, Zhao Y, Cao S, Su A, Zhang X, et al. A rare case of multicentric castleman’s disease transforms into multiple myeloma and its successful treatment. Cancer Biol Ther 2018;19:949-952.
  17. Yuan ZG, Dun XY, Li YH, Hou J. Treatment of multicentric Castleman’s Disease accompanying multiple myeloma with bortezomib: a case report. J Hematol Oncol 2009;28:2-19.
  18. Khan AA, Siraj F, Bhargava M, Aggarwal S. Successful treatment of multicentric Castleman’s disease accompanying myeloma with bortezomib. BMJ Case Rep 2012;20:2012:bcr2012007646.

Published

2024-09-23

Issue

Vol. 11 No. 10 (2024)

Categories

How to Cite

1.
Ismayilov R, Cinar OE, Ozdede M, Ozogul E, Malkan UY, Uner A, et al. Coexistence of HHV-8-associated plasmacytic multicentric Castleman disease, Kaposi’s sarcoma, and multiple myeloma in a HIV-negative patient. EJCRIM [Internet]. 2024 Sep. 23 [cited 2026 Nov. 3];11(10). Available from: https://ejcrim.com/index.php/ejcrim/article/view/4876